Literature DB >> 18842730

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.

Georgia D Tomaras1, Nicole L Yates, Pinghuang Liu, Li Qin, Genevieve G Fouda, Leslie L Chavez, Allan C Decamp, Robert J Parks, Vicki C Ashley, Judith T Lucas, Myron Cohen, Joseph Eron, Charles B Hicks, Hua-Xin Liao, Steven G Self, Gary Landucci, Donald N Forthal, Kent J Weinhold, Brandon F Keele, Beatrice H Hahn, Michael L Greenberg, Lynn Morris, Salim S Abdool Karim, William A Blattner, David C Montefiori, George M Shaw, Alan S Perelson, Barton F Haynes.   

Abstract

A window of opportunity for immune responses to extinguish human immunodeficiency virus type 1 (HIV-1) exists from the moment of transmission through establishment of the latent pool of HIV-1-infected cells. A critical time to study the initial immune responses to the transmitted/founder virus is the eclipse phase of HIV-1 infection (time from transmission to the first appearance of plasma virus), but, to date, this period has been logistically difficult to analyze. To probe B-cell responses immediately following HIV-1 transmission, we have determined envelope-specific antibody responses to autologous and consensus Envs in plasma donors from the United States for whom frequent plasma samples were available at time points immediately before, during, and after HIV-1 plasma viral load (VL) ramp-up in acute infection, and we have modeled the antibody effect on the kinetics of plasma viremia. The first detectable B-cell response was in the form of immune complexes 8 days after plasma virus detection, whereas the first free plasma anti-HIV-1 antibody was to gp41 and appeared 13 days after the appearance of plasma virus. In contrast, envelope gp120-specific antibodies were delayed an additional 14 days. Mathematical modeling of the earliest viral dynamics was performed to determine the impact of antibody on HIV replication in vivo as assessed by plasma VL. Including the initial anti-gp41 immunoglobulin G (IgG), IgM, or both responses in the model did not significantly impact the early dynamics of plasma VL. These results demonstrate that the first IgM and IgG antibodies induced by transmitted HIV-1 are capable of binding virions but have little impact on acute-phase viremia at the timing and magnitude that they occur in natural infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18842730      PMCID: PMC2593361          DOI: 10.1128/JVI.01708-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells.

Authors:  Vincent Holl; Maryse Peressin; Thomas Decoville; Sylvie Schmidt; Susan Zolla-Pazner; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection.

Authors:  Penny L Moore; Elin S Gray; Isaac A Choge; Nthabeleng Ranchobe; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

3.  Viral dynamics of acute HIV-1 infection.

Authors:  S J Little; A R McLean; C A Spina; D D Richman; D V Havlir
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

Review 4.  Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV.

Authors:  Weidong Xu; Regina Hofmann-Lehmann; Harold M McClure; Ruth M Ruprecht
Journal:  Vaccine       Date:  2002-05-06       Impact factor: 3.641

5.  Modeling plasma virus concentration during primary HIV infection.

Authors:  M A Stafford; L Corey; Y Cao; E S Daar; D D Ho; A S Perelson
Journal:  J Theor Biol       Date:  2000-04-07       Impact factor: 2.691

6.  Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions.

Authors:  Kehmia Titanji; Francesca Chiodi; Rino Bellocco; Danika Schepis; Lyda Osorio; Chiara Tassandin; Giuseppe Tambussi; Sven Grutzmeier; Lucia Lopalco; Angelo De Milito
Journal:  AIDS       Date:  2005-11-18       Impact factor: 4.177

7.  Is human immunodeficiency virus RNA load composed of neutralized immune complexes?

Authors:  Ferdinando Dianzani; Guido Antonelli; Elisabetta Riva; Ombretta Turriziani; Laura Antonelli; Stephen Tyring; Daniel A Carrasco; Hung Lee; Derrick Nguyen; Jingzhi Pan; Joyce Poast; Miles Cloyd; Samuel Baron
Journal:  J Infect Dis       Date:  2002-04-01       Impact factor: 5.226

8.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

9.  Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design.

Authors:  Nancy Gasper-Smith; Deanna M Crossman; John F Whitesides; Nadia Mensali; Janet S Ottinger; Steven G Plonk; M Anthony Moody; Guido Ferrari; Kent J Weinhold; Sara E Miller; Charles F Reich; Li Qin; Stephen G Self; George M Shaw; Thomas N Denny; Laura E Jones; David S Pisetsky; Barton F Haynes
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

10.  Post-exposure prophylaxis for SIV revisited: animal model for HIV prevention.

Authors:  Peter Emau; Yonghou Jiang; Michael B Agy; Baoping Tian; Girma Bekele; Che-Chung Tsai
Journal:  AIDS Res Ther       Date:  2006-11-28       Impact factor: 2.250

View more
  373 in total

1.  Rapid HIV Progression Is Associated with Extensive Ongoing Somatic Hypermutation.

Authors:  Ben S Wendel; Yajing Fu; Chenfeng He; Stefany M Hernandez; Mingjuan Qu; Zining Zhang; Yongjun Jiang; Xiaoxu Han; Junjie Xu; Haibo Ding; Ning Jiang; Hong Shang
Journal:  J Immunol       Date:  2020-06-26       Impact factor: 5.422

2.  Key Concepts in the Early Immunology of HIV-1 Infection.

Authors:  Basile Siewe; Alan Landay
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

3.  HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.

Authors:  Bimal K Chakrabarti; Marie Pancera; Sanjay Phogat; Sijy O'Dell; Krisha McKee; Javier Guenaga; James Robinson; John Mascola; Richard T Wyatt
Journal:  AIDS Res Hum Retroviruses       Date:  2011-01-19       Impact factor: 2.205

4.  Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection.

Authors:  Nicole L Yates; Judith T Lucas; Tracy L Nolen; Nathan A Vandergrift; Kelly A Soderberg; Kelly E Seaton; Thomas N Denny; Barton F Haynes; Myron S Cohen; Georgia D Tomaras
Journal:  AIDS       Date:  2011-11-13       Impact factor: 4.177

5.  Post-treatment control of HIV infection.

Authors:  Jessica M Conway; Alan S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

6.  Maternal Humoral Immune Correlates of Peripartum Transmission of Clade C HIV-1 in the Setting of Peripartum Antiretrovirals.

Authors:  Charmaine P Mutucumarana; Joshua Eudailey; Erin P McGuire; Nathan Vandergrift; Gerald Tegha; Charles Chasela; Sascha Ellington; Charles van der Horst; Athena P Kourtis; Sallie R Permar; Genevieve G Fouda
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

7.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Authors:  Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert
Journal:  N Engl J Med       Date:  2013-10-07       Impact factor: 91.245

8.  High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Authors:  Katie L Davis; Elin S Gray; Penny L Moore; Julie M Decker; Aidy Salomon; David C Montefiori; Barney S Graham; Michael C Keefer; Abraham Pinter; Lynn Morris; Beatrice H Hahn; George M Shaw
Journal:  Virology       Date:  2009-03-18       Impact factor: 3.616

9.  HIV-Selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection.

Authors:  Surender Khurana; Philip J Norris; Michael P Busch; Barton F Haynes; Susan Park; Pretty Sasono; Koleka Mlisana; Abdool Karim Salim; Frederick M Hecht; Joseph Mulenga; Elwyn Chomba; Eric Hunter; Susan Allen; George Nemo; Isaac R Rodriguez-Chavez; Joseph B Margolick; Hana Golding
Journal:  J Clin Microbiol       Date:  2009-11-11       Impact factor: 5.948

10.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.